Sign in
Taking people in NetherlandsPhase 4

Comparing rituximab with cyclophosphamide to rituximab alone in ANCA vasculitis

Tests rituximab with or without cyclophosphamide in adults with ANCA vasculitis.

Key facts

Who runs it
Academisch Ziekenhuis Leiden
Where
's-Gravenhage, Alkmaar, Amersfoort, Amsterdam, Breda, Leiden, and Rotterdam, NetherlandsSee the 8 sites
Registry title
Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients
Status
Recruiting
Phase
Phase 4
People taking part
100 people, planned
Started
3 May 2019
Expected to end
1 Jun 2027
Type of study
Interventional
Record updated
11 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with ANCA-associated vasculitis (GPA or MPA) that affects at least one major organ and needs treatment with cyclophosphamide or rituximab.

Age
18 years or older
Sex
All sexes
Disease stage
Newly diagnosed or relapsed generalised disease: granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), with at least one major organ involved (for example kidney, lung, heart, or the nervous system).
Earlier treatment
Must not have needed dialysis or plasma exchange within 12 weeks before screening. Must not have had more than 3000mg methylprednisolone equivalent of intravenous glucocorticoids within 4 weeks before screening. Must not have had a live vaccine 1 month before screening.
Biomarker or test result
A positive test for anti-PR3 or anti-MPO, either now or in the past.

Main reasons for not taking part

  • Pregnant or breast-feeding
  • Positive HIV test, or hepatitis B or untreated hepatitis C
  • Very low antibody levels (IgG < 4.0 g/L or IgA < 0.1 g/L) or a primary immunodeficiency
  • Active infection that does not fit with starting treatment
  • Past severe allergic reaction to contrast agents, human or murine proteins, or monoclonal antibodies

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Clinical diagnosis of granulomatosis with polyangiitis (GPA) or microscopic Polyangiitis (MPA), consistent with Chapel-Hill Consensus Conference definitions
  • Aged at least 18 years, with newly-diagnosed or relapsed AAV with ‘generalised disease’, defined as involvement of at least one major organ (e.g. kidney, lung, heart, peripheral or central nervous system), requiring induction treatment with cyclophosphamide or rituximab
  • Positive test for anti-PR3 or anti-MPO (current or historic)
  • Willing and able to give written Informed Consent and to comply with the requirements of the study protocol

Who cannot take part

  • Required dialysis or plasma exchange within 12 weeks prior to screening
  • Received intravenous glucocorticoids, >3000mg methylprednisolone equivalent, within 4 weeks prior to screening
  • Immunization with a live vaccine 1 month before screening
  • Active infection not compatible with start of remission-induction therapy in the opinion of the treating physician and/or investigator, e.g.: - Serological evidence of viral hepatitis defined as: patients positive for HbsAg test or HBcAb or a positive hepatitis C antibody not treated with antiviral medication - Have a historically positive HIV test or test positive at screening for HIV
  • History or presence of any medical condition or disease which, in the opinion of the Investigator, may place the patient at unacceptable risk for study participation
  • Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies
  • Have a history of a primary immunodeficiency
  • Have a significant infection history that in the opinion of the investigator would make the candidate unsuitable for the study
  • Active pregnancy, as proven by a positive urine beta-HCG test or a positive serum beta-HCG
  • Significant hypogammaglobulinemia (IgG < 4.0 g/L) or an IgA deficiency (IgA < 0.1 g/L)
  • Have a neutrophil count of < 1.5x10E9/L
  • Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin > 3 times the upper limit of normal before start of dosing
  • Have any other clinically significant abnormal laboratory value in the opinion of the investigator
  • Pregnant or breast-feeding

Where in Netherlands

  • Haga Hospital's-Gravenhage, NetherlandsTaking people
  • Noordwest Ziekenhuisgroep StichtingAlkmaar, NetherlandsTaking people
  • Meander Medisch CentrumAmersfoort, NetherlandsTaking people
  • Stichting Amsterdam UMCAmsterdam, NetherlandsTaking people
  • Amphia HospitalBreda, NetherlandsTaking people
  • Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people
  • Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
  • Sint Franciscus Vlietland Groep StichtingRotterdam, NetherlandsTaking people

About the trial

What the trial wants to find out

The primary objective is the number of RTX infusions needed to maintain clinical remission over 2 years

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients (The ENDURRANCE-1 Study)
Plain-language title
Comparing rituximab with cyclophosphamide to rituximab alone in ANCA vasculitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 August 2025